MDRX Related Analyst Ratings
-
Citi Upgrades Allscripts (MDRX) to Buy
-
Morgan Stanley Upgrades Allscripts (MDRX) to Overweight
-
Maxim Group Downgrades Allscripts (MDRX) to Hold
-
Jefferies Lifts PT on Cerner (CERN) to $110
-
B. Riley Starts Allscripts (MDRX) at Neutral
-
Credit Suisse Upgrades Allscripts (MDRX) to Outperform
-
Allscripts (MDRX) Gives Bulls Some Hope, PT Raised - Jefferies
-
Raymond James Upgrades Allscripts (MDRX) to Strong Buy
-
Avondale Partners Upgrades Allscripts (MDRX) to Market Outperform
-
Argus Downgrades Allscripts (MDRX) to Hold
-
JMP Securities Resumes Allscripts (MDRX) at Market Perform
-
Piper Jaffray Downgrades Allscripts (MDRX) to Underweight
-
New Allscripts (MDRX) CFO Won't Affect M&A Potential - Analyst
-
Cowen Upgrades Allscripts (MDRX) to Outperform
-
ISI Group Upgrades Allscripts (MDRX) to Overweight
-
UPDATE: Piper Says 'Challenges' Lowers Allscripts (MDRX) Takeover Value, Sees Bids at $14/Share
-
JPMorgan Upgrades Allscripts (MDRX) to Overweight
-
ISI Group Starts Allscripts (MDRX) at Market Weight
-
Leerink Swann Maintains a 'Market Perform' on Allscripts (MDRX);
-
Wells Fargo Starts Allscripts (MDRX) at Market Perform; Long-term Growth Prospects Muted
-
Lazard Starts ATHN, CERN, QSII, MDAS at Buy, MDRX, OMCL, CPSI, EHTH at Neutral, EPOC at Sell
-
William Blair Downgrades Allscripts (MDRX) to Market Perform
-
UPDATE - UBS Downgraded Allscripts (MDRX) to Neutral; Surprise! Miss on All Fronts, and Mgmt Goes
-
Avondale Partners Downgrades Allscripts (MDRX) Two Notches to 'Underperform'
-
Oppenheimer Downgrades Allscripts (MDRX) to Perform
-
Barclays Downgrades Allscripts (MDRX) to Equalweight
-
Cowen Downgrades Allscripts (MDRX) to Neutral
-
UBS Downgrades Allscripts (MDRX) to Neutral
-
Piper Jaffray Downgrades Allscripts (MDRX) to Neutral
-
Credit Suisse Downgrades Allscripts-Misys Healthcare (MDRX) to Neutral
-
Caris & Co. Downgrades Allscripts-Misys Healthcare (MDRX) to Average
-
Jefferies Downgrades Allscripts-Misys Healthcare (MDRX) to Hold
-
UPDATE - Auriga Downgraded Allscripts-Misys Healthcare (MDRX) to Hold; Challenging Growth
-
Auriga Downgrades Allscripts-Misys Healthcare (MDRX) to Hold
-
JPMorgan Downgrades Allscripts-Misys Healthcare (MDRX) to Neutral
-
Piper Jaffray Says Buy the Dip in Allscripts (MDRX) But Traders Keep Selling
-
Credit Suisse Starts Allscripts-Misys Healthcare (MDRX) at Outperform
-
Auriga on Healthcare IT & Services: HIMSS Themes - Accountability, Data Exchange, Population Health & Analytics
-
Leerink Swann Downgrades Allscripts-Misys Healthcare (MDRX) to Market Perform; Challenges Persist
-
Raymond James Downgrades Allscripts-Misys Healthcare (MDRX) to Outperform
-
Sterne Agee Starts Allscripts-Misys Healthcare (MDRX) at Buy
-
Barclays Maintains an 'Overweight' on Allscripts-Misys Healthcare (MDRX); Down Under now a Done Deal
-
Jefferies Starts Allscripts-Misys Healthcare (MDRX) at Buy
-
Deutsche Bank Reiterates a 'Buy' on Allscripts-Misys Healthcare (MDRX); Bookings Highlight 3Q, Focus Shifts 'Down Under' for 4Q
-
Avondale Partners Starts Allscripts-Misys Healthcare (MDRX) at Market Outperform
-
Auriga Reiterates a 'Buy' on Allscripts-Misys Healthcare (MDRX); Going Mobile: iPhone App Reduces Barriers to Physician Adoption
-
Piper Jaffray Upgrades Allscripts-Misys Healthcare (MDRX) to Overweight
-
Raymond James Upgrades Allscripts-Misys Healthcare (MDRX) to Strong Buy
-
Auriga Upgrades Allscripts-Misys Healthcare (MDRX) to Buy; All Aboard Allscripts (Again!)
-
Goldman Sachs Starts Allscripts-Misys Healthcare (MDRX) at Neutral
Back to MDRX Stock Lookup
